Рет қаралды 69,962
First of new generation of cancer drugs granted European approval
A new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
www.youtube.com...